Symbiotec Pharmalab Limited

• Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company₹113 Cr
• General corporate purposes

Except as stated below, there are no outstanding (i) criminal proceedings involving the Company, Subsidiaries, Directors or Promoters and Key Managerial Personnel and Senior Management; (ii) actions by regulatory authorities and statutory authorities involving the Relevant Parties and Key Managerial Personnel and Senior Management; (iii) disciplinary actions including penalties imposed by SEBI or stock exchanges against promoters in the last five financial years; (iv) outstanding claims related to direct and indirect taxes involving the Relevant Parties; and (v) other outstanding litigation involving the Relevant Parties (including civil litigation or arbitration proceedings) which have been determined to be material pursuant to the Materiality Policy. The Materiality Threshold is ₹51.12 million. Pre-litigation notices received from third parties (excluding governmental / tax / statutory / regulatory / judicial authorities or notices threatening criminal action) shall in any event not be considered as litigation until impleaded as a party.

• Our revenue is highly concentrated in the sale of APIs, which constituted 96.07%, 99.10% and 100.00% of revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for APIs, and our top products in particular, or disruption in production, could have an adverse effect on our business, results of operations, financial condition and cash flows.(Revenue Concentration)

• Our top five products contributed 62.27%, 63.16% and 60.37% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for API products, and our top products in particular, or a temporary or permanent discontinuation in our manufacturing operations for such products, could have an adverse effect on our business, results of operations, financial condition and cash flows.(Revenue Concentration)

• Our manufacturing facilities are subject to periodic inspections and audits by regulatory authorities and our customers. Any manufacturing or quality control failures may subject us to regulatory action, damage our reputation and have an adverse effect on our business, results of operations, financial condition and cash flows.(Regulatory Compliance)

• We cannot assure you that we will obtain approvals for the Biologics Facility in a timely manner, or at all. We are required to comply with regulations and quality standards stipulated by regulatory authorities and certain of our customers.(Regulatory Compliance)

• If our API production is interrupted due to equipment failure, supply chain disruptions, regulatory non-compliance, or other operational challenges, or if we fail to procure high-quality APIs in the quantities we require on a cost-effective basis, the sales and distribution of our products could be delayed or interrupted.(Operational Risk)

• We are required to comply with regulations and quality standards stipulated by regulatory authorities and certain of our customers. If we are not in compliance with the requirements prescribed by such authorities or terms stipulated in contracts with our customers, we may be subject to regulatory actions, including issuance of warning letters, imposition of sanctions, amendment or withdrawal of approvals.(Regulatory Compliance)

• We are expanding our biologics capacity by adding a proposed dedicated 14 KL (comprising two reactors of 7 KL each) fermentation capacity for biologics manufacturing in our Ujjain Facility, to cater to the increasing demand for GLP-1 and Insulin.(Business Strategy)

• We have commissioned the Mhow Facility, which is a dedicated injectables facility. This facility, which has been established with an investment of ₹ 3,919.19 million as of March 31, 2026, is a key part of our strategy to enter high-value, technology-driven complex injectables.(Business Strategy)

Each bar is a fixed formula applied to the figures shown above, scored 0–100. This is a reading of what the company disclosed — not a recommendation to apply or avoid, not a price target, and not a prediction of listing performance. Dimensions that could not be extracted are excluded rather than assumed, so coverage varies between documents.